Related Experiment Video

Updated: Jun 1, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Raf kinases in cancer-roles and therapeutic opportunities

G Maurer1, B Tarkowski, M Baccarini

  • 1Max F Perutz Laboratories, Center for Molecular Biology, University of Vienna, Vienna, Austria.

Oncogene
|May 18, 2011
PubMed

Insights

RAF proteins are key in cancer development and proliferation. Targeted RAF inhibitor therapies show promise for treating cancers like melanoma, offering new therapeutic avenues.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • RAF proteins (A-RAF, B-RAF, C-RAF) are serine/threonine kinases involved in cell signaling.
  • RAF kinases are activated by the RAS oncogene and mediate both kinase-dependent and independent functions.
  • The MEK/ERK pathway, regulated by RAF, is crucial for cell proliferation and implicated in various human tumors.

Purpose of the Study:

  • To review the role of BRAF and CRAF in carcinogenesis.
  • To discuss the efficacy of molecular therapies targeting RAF in cancer treatment.
  • To highlight the challenges associated with RAF-targeted therapies.

Main Methods:

  • Literature review of studies on RAF proteins, carcinogenesis, and targeted therapies.
  • Analysis of clinical data on RAF inhibitor efficacy, particularly in melanoma.
  • Synthesis of information on the mechanisms of RAF-dependent and independent functions.

Main Results:

  • Activating BRAF mutations are found in a subset of human tumors.
  • Small-molecule RAF inhibitors have demonstrated significant response rates in melanoma patients.
  • RAF proteins play a critical role in tumor promotion and progression.

Conclusions:

  • RAF proteins are validated molecular targets for anticancer therapy.
  • Targeted inhibition of RAF, particularly BRAF, offers a promising therapeutic strategy for specific cancers.
  • Further research is needed to overcome challenges and optimize RAF-targeted treatments.

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...